NASDAQ: SYRESpyre Therapeutics Inc Stock
$35.58+1.27 (+3.7%)
Updated Apr 18, 2024
SYRE Price
$35.58
Fair Value Price
$15.09
Market Cap
$1.29B
52 Week Low
$2.66
52 Week High
$47.97
P/E
-0.72x
P/B
6.99x
P/S
167.52x
PEG
N/A
Dividend Yield
N/A
Revenue
$886.00k
Earnings
-$338.79M
Gross Margin
100%
Operating Margin
-38,241.08%
Profit Margin
-38,238.1%
Debt to Equity
0.4
Operating Cash Flow
-$100M
Beta
1.21
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SYRE Overview
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SYRE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SYRE ($35.58) is overvalued by 135.83% relative to our estimate of its Fair Value price of $15.09 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SYRE ($35.58) is not significantly undervalued (135.83%) relative to our estimate of its Fair Value price of $15.09 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SYRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SYRE due diligence checks available for Premium users.
Be the first to know about important SYRE news, forecast changes, insider trades & much more!
SYRE News
Valuation
SYRE fair value
Fair Value of SYRE stock based on Discounted Cash Flow (DCF)
Price
$35.58
Fair Value
$15.09
Overvalued by
135.83%
SYRE ($35.58) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SYRE ($35.58) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SYRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SYRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.72x
Industry
15.68x
Market
41.33x
SYRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.99x
Industry
5.76x
SYRE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SYRE's financial health
Profit margin
Revenue
$0.0
Net Income
-$63.2M
Profit Margin
0%
SYRE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SYRE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$341.9M
Liabilities
$73.3M
Debt to equity
0.4
SYRE's short-term assets ($341.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SYRE's short-term assets ($341.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SYRE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SYRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$31.0M
Investing
-$35.3M
Financing
$163.6M
SYRE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SYRE vs Biotech Stocks
Spyre Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.